Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912804 | 0.73 | LMNA (0.40) | ALDH1A1LMNA | |
| SCHEMBL2912805 | 0.72 | — | — | |
| SCHEMBL15887085 | 0.72 | — | — | |
| SCHEMBL27786380 | 0.70 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27505436 | 0.70 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27786849 | 0.70 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27832027 | 0.70 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL27815197 | 0.70 | LMNA (0.36) | ALDH1A1LMNA | |
| Water SCHEMBL27952503 | 0.68 | LMNA (0.35) | ALDH1A1LMNA | |
| SCHEMBL28821320 | 0.68 | USP2 (0.49) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250084051-A1 | glycerylphosphorylethanolamine (GPE) compound and lipid nanoparticle (LNP)-based drug carrier with same | SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES (CN) | 2025-03-13 | — | — | US | claimed |
| EP-3490677-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Berg LLC (US) | 2019-06-05 | — | — | EP | claimed |
| US-20180024132-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BERG LLC | 2018-01-25 | — | — | US | claimed |
| WO-2018009834-A1 | LIPID, PROTEIN, AND METABOLITE MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BERG LLC (US) | 2018-01-11 | — | — | WO | claimed |
| EP-3019195-A2 | COMPOSITION AND RELATIVE KIT FOR PERIODONTAL, IMPLANTOLOGY, AND ENDODONTIC TREATMENT HAVING AN OPTIMISED ANTISEPTIC AND REGENERATING ACTION | Caccianiga, Gianluigi (IT) | 2016-05-18 | — | — | EP | claimed |
| WO-2015004589-A2 | COMPOSITION AND RELATIVE KIT FOR PERIODONTAL, IMPLANTOLOGY, AND ENDODONTIC TREATMENT HAVING AN OPTIMIZED ANTISEPTIC AND REGENERATING ACTION | RINI, Valerio (IT) | 2015-01-15 | — | — | WO | claimed |
| CN-102532190-B | Method utilizing column chromatography to prepare high-purity L-alpha glyceryl phosphoryl ethanolamine | UNIV JIANGNAN | 2014-12-24 | — | — | CN | claimed |
| CN-102532190-A | Method utilizing column chromatography to prepare high-purity L-alpha glyceryl phosphoryl ethanolamine | UNIV JIANGNAN | 2012-07-04 | — | — | CN | claimed |
| EP-1399172-A1 | SEAL-OIL-BASED PHARMACEUTICAL, COSMETIC, DERMO-COSMETIC, HYGIENE, ALIMENTARY AND PARA-ALIMENTARY (FOOD-SUPPLEMENTS) PRODUCTS; THEIR METHODS OF PREPARATION; THEIR USES AS PREVENTIVE AND/OR AS THERAPEUTIC AGENTS | Fundaçao Esspritt-Icarus (Fundaçao Europeia de Investigaçao Medica) NGO IPSS (PT) | 2004-03-24 | — | — | EP | claimed |
| WO-2002013838-A1 | SEAL-OIL-BASED PHARMACEUTICAL, COSMETIC, DERMO-COSMETIC, HYGIENE, ALIMENTARY AND PARA-ALIMENTARY (FOOD-SUPPLEMENTS) PRODUCTS; THEIR METHODS OF PREPARATION; THEIR USES AS PREVENTIVE AND/OR AS THERAPEUTIC AGENTS | FUNDAÇAO ESSPRIT-ICARUS (FUNDAÇAO EUROPEIA DE INVESTIGAÇAO MEDICA), NGO; IPSS. (PT) | 2002-02-21 | — | — | WO | claimed |
| JP-2883202-B2 | — | — | 1999-04-19 | — | — | JP | claimed |
| EP-0803246-A1 | Compositions for topical application based on thermal muds and gelling agents | APR APPLIED PHARMA RESEARCH S.A. (CH) | 1997-10-29 | — | — | EP | claimed |
| US-5250719-A | Process for the preparation of L-α-glycerylphosphoryl-choline and of L-α-glycerylphosphorylethanolamine | PRIME EUROPEAN THERAPEUTICALS S.P.A. (IT) | 1993-10-05 | — | — | US | claimed |
| EP-0471706-A1 | PROCESS FOR THE PREPARATION OF L-ALPHA-GLYCERYLPHOSPHORYLCHOLINE AND OF L-ALPHA-GLYCERYLPHOSPHORYLETHANOLAMINE. | ISTITUTO CHEMIOTERAPICO (IT) | 1992-02-26 | — | — | EP | claimed |
| WO-1990013552-A1 | PROCESS FOR THE PREPARATION OF L-α-GLYCERYLPHOSPHORYLCHOLINE AND OF L-α-GLYCERYLPHOSPHORYLETHANOLAMINE | ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.P.A. (IT) | 1990-11-15 | — | — | WO | claimed |
| EP-0217765-B1 | PROCESS FOR THE PREPARATION OF L-ALPHA-GLYCERYLPHOSPHORYLCHOLINE, L-ALPHA-GLYCERYLPHOSPHORYLETHANOLAMINE FROM CRUDE AND/OR DEOLEATED LECITHINS | ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.p.A. (IT) | 1990-08-16 | — | — | EP | claimed |
| EP-0217765-A2 | Process for the preparation of L-alpha-glycerylphosphorylcholine, L-alpha-glycerylphosphorylethanolamine from crude and/or deoleated lecithins | ISTITUTO CHEMIOTERAPICO ITALIANO FINE CHEMICALS S.p.A. (IT) | 1987-04-08 | — | — | EP | claimed |
| JP-61129191-A | — | — | None | — | — | JP | disclosed |
| JP-S61129191-A | GLYCEROPHOSPHOLIPID CONTAINING DECOSAHEXAENOIC ACID | NIPPON OIL & FATS CO LTD | 1986-06-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084051-A1 | glycerylphosphorylethanolamine (GPE) compound and lipid nanoparticle (LNP)-based drug carrier with same | PHOSPHO1, SGPL1, PCTP | ALDH1A1 1816/4885LMNA 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.